| Technology evaluation: C242-DM1, ImmunoGen Inc. | |
| | |
MedLine Citation:
|
PMID: 11338934 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
C242-DM1 is a tumor-activated immunotoxin under development by GlaxoSmithKline plc (formerly SmithKline Beecham plc), under licence from ImmunoGen Inc, as a potential treatment for colon tumor. It consists of a colon cancer-specific humanized antibody, C242, conjugated to the maytansine derivative DM1. In preclinical studies, C242-DM1 caused complete tumor regression in animal models of both human pancreatic and non-small cell lung cancer (NSCLC) at non-toxic doses. C242-DM1 has also been evaluated in an immunoconjugate combination with J-591 (Cornell University). The J591-DM1 immunoconjugate demonstrated effective, antigen-specific delivery of a highly cytotoxic drug to PSMA-positive Pca cells in vitro and in vivo with low systemic toxicity. Results from studies in monkeys showed that C242-DM1 had no significant toxicity or side effects, when administered at doses higher than those that were previously shown to completely eradicate human colon tumors in mice [271420]. ImmunoGen acquired the right to evaluate, and an option to license, technology related to maytansines from Takeda. In February 1999, ImmunoGen and SmithKline Beecham signed a US $45 million development and commercialization agreement for C242-DM1 [313493]. In August 1997, Immunogen received an SBIR grant to advance development of huC242-DM1 [258356]. EP-00425235, held by ImmunoGen, covers conjugated forms of ansamitocin (maytansine) derivatives. Takeda holds several patents for the production of ansamitocin and its analogs, the first one being JP-53124692. |
| | |
Authors:
|
S Smith |
Related Documents
:
|
11522634 - Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine... 15800914 - Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. 11251964 - Induction of human tumor-loaded dendritic cells. 7680054 - Variations in the distribution, frequency, and phenotype of langerhans cells during the... 22135084 - Organotypic explant culture of glioblastoma multiforme and subsequent single-cell suspe... 12083304 - A novel design of thermal anomaly for mammary gland tumor phantom for microwave radiome... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current opinion in molecular therapeutics Volume: 3 ISSN: 1464-8431 ISO Abbreviation: Curr. Opin. Mol. Ther. Publication Date: 2001 Apr |
Date Detail:
|
Created Date: 2001-05-07 Completed Date: 2001-12-05 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100891485 Medline TA: Curr Opin Mol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 198-203 Citation Subset: IM |
Affiliation:
|
Suzanne_Smith162@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal / chemistry, pharmacology*, therapeutic use Antineoplastic Agents, Phytogenic / chemical synthesis, chemistry, pharmacology*, therapeutic use Clinical Trials, Phase I as Topic Colonic Neoplasms / drug therapy*, immunology Humans Immunotoxins / chemistry, pharmacology*, therapeutic use Maytansine / chemical synthesis, chemistry, pharmacology*, therapeutic use Molecular Structure Structure-Activity Relationship |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antineoplastic Agents, Phytogenic; 0/Immunotoxins; 35846-53-8/Maytansine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hydrodynamics-based gene delivery.
Next Document: Technology evaluation: CV-787, Calydon Inc.